Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML.

Leukemia & lymphoma - 1 Feb 2025

Chin Kuo-Kai, Derkach Andriy, Famulare Christopher, Gupta Gaurav K, Borge P Dayand, Geyer Mark B, Goldberg Aaron D, Haque Tamanna, Park Jae H, Roeker Lindsey E, Tallman Martin S, Stahl Maximilian, Stein Eytan M

Abstract excerpt

Hypomethylating agents (HMA) and venetoclax (VEN) are commonly used in patients with IDH-mutated (IDHm) acute myeloid leukemia (AML) ineligible for induction chemotherapy. While prior studies demonstrated high response and survival rates with HMA/VEN in IDHm AML, the impact of treatment modifications in real-world settings is unclear. We retrospectively reviewed 89 IDHm AML patients treated with HMA/VEN from...

Topics

Join the communities discussing this publication.

Antineoplastic Combined Chemotherapy Protocols
Bridged Bicyclo Compounds, Heterocyclic
Isocitrate Dehydrogenase
Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39397429
DOI: 10.1080/10428194.2024.2411436
PMCID: PMC12642954

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML.PMID 39397429Read ↗

Ivosidenib or venetoclax combined with hypomethylating agents in IDH1-mutated acute myeloid leukemia: a real-world studySemantic proximity Read ↗

Venetoclax and hypomethylating agents in FLT3 ‐mutated acute myeloid leukemiaSemantic proximity Read ↗

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agentsSemantic proximity Read ↗

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.Semantic proximity Read ↗

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimensSemantic proximity Read ↗

Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Study in Chinese PatientsSemantic proximity Read ↗

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registrySemantic proximity Read ↗

Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China.Semantic proximity Read ↗

The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.Semantic proximity Read ↗

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

Advancements and Challenges in the Treatment of AML.Semantic proximity Read ↗

Real-life Multicenter Experience of Long-term Treatment With Venetoclax Plus Azacitidine for Acute Myeloid Leukemia in ChinaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.